Home Tags SN-38

Tag: SN-38

New U.S. Patent and Updated Clinical Development Plan for Sacituzumab Govitecan

Immunomedics, a clinical-stage biopharmaceutical company developing antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases, has received a new patent (U.S....

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients...

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results

Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...

ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers

With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...

Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

An interim analysis of a mid-stage clinical study showed that labetuzumab govitecan, also known as  (IMMU-130), a novel antibody-drug conjugates or ADC being developed by...

New Data on Novel ADC For Solid Cancer Presented at Joint...

Clinical data on IMMU-132, an anti-TROP-2-SN-38 Anitbody-drug Conjugate currently being evaluated in patients with solid tumors, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and...

Linker Stability Enhances Efficacy of Antibody-SN-38

Results from ongoing studies of two bispecific, hexavalent, antibodies, 1R-(E1)-(E1) and 1R-(15)-(15), for treating breast, pancreatic and other solid cancers, were presented during a...